Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerRespiratory

PUBLISHER: Grand View Research | PRODUCT CODE: 1553626

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553626

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment, By End Use, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is anticipated to reach USD 9.3 billion by 2030, growing at a CAGR of 11.3% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2023, the chemotherapy segment accounted for the largest revenue share of 33.2% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 64.3% in 2023. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
Show more
Product Code: GVR-4-68040-431-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The increasing incidence of lung cancer
      • 3.2.1.2. Advancements in targeted therapies and immunotherapies
      • 3.2.1.3. The growing emphasis on personalized medicine
      • 3.2.1.4. The rising demand for early detection and screening programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Limited availability of skilled healthcare professionals
  • 3.3. Metastatic Lung Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global Metastatic Lung Adenocarcinoma Treatment Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Eli Lilly and Company
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. AstraZeneca
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bristol-Myers Squibb Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA (EMD Serono)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. F. Hoffmann-La Roche
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. GSK Plc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. AbbVie Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-431-1

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 7 Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 11 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 12 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 14 Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 20 Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22 Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 33 China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 34 China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 53 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: Market Outlook
  • Fig. 14 Metastatic Lung Adenocarcinoma Treatment Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Metastatic Lung Adenocarcinoma Treatment Market Driver Impact
  • Fig. 18 Metastatic Lung Adenocarcinoma Treatment Market Restraint Impact
  • Fig. 19 Metastatic Lung Adenocarcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 20 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
  • Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 25 Radiation Therapy market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • Fig. 28 Metastatic Lung Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
  • Fig. 29 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 30 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 Global Metastatic lung adenocarcinoma treatment Market: Regional Movement Analysis
  • Fig. 33 Global Metastatic lung adenocarcinoma treatment Market: Regional Outlook And Key Takeaways
  • Fig. 34 Global Metastatic lung adenocarcinoma treatment market share and leading players
  • Fig. 35 North America, by country
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Italy key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Norway key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia key country dynamics
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Market share of key market players- Metastatic lung adenocarcinoma treatment market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!